An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
Public ClinicalTrials.gov record NCT02667587. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase 3 Single Blind Study of Temozolomide Plus Radiation Therapy Combined With Nivolumab or Placebo in Newly Diagnosed Adult Subjects With MGMT-Methylated (Tumor O6-methylguanine DNA Methyltransferase) Glioblastoma
Study identification
- NCT ID
- NCT02667587
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 716 participants
Conditions and interventions
Conditions
Interventions
- Nivolumab Drug
- Nivolumab Placebo Other
- Radiotherapy Radiation
- Temozolomide Drug
Drug · Other · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 8, 2016
- Primary completion
- Dec 21, 2020
- Completion
- Apr 8, 2024
- Last update posted
- Jun 17, 2025
2016 – 2024
United States locations
- U.S. sites
- 35
- U.S. states
- 23
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0023 | Birmingham | Alabama | 35294-3410 | — |
| Local Institution - 0003 | Phoenix | Arizona | 85013 | — |
| Cedars Sinai Medical Center | Los Angeles | California | 90048 | — |
| Local Institution - 0010 | Los Angeles | California | 90095-1769 | — |
| Local Institution - 0128 | Sacramento | California | 95816 | — |
| Local Institution - 0029 | San Diego | California | 92123 | — |
| Local Institution - 0006 | San Francisco | California | 94143-0372 | — |
| Local Institution - 0004 | New Haven | Connecticut | 06520 | — |
| Local Institution - 0031 | Washington D.C. | District of Columbia | 20007 | — |
| Local Institution - 0087 | Miami | Florida | 33136 | — |
| Local Institution - 0030 | Tampa | Florida | 33612 | — |
| Local Institution - 0022 | Chicago | Illinois | 60637 | — |
| Local Institution - 0060 | Westwood | Kansas | 66205 | — |
| Local Institution - 0018 | Louisville | Kentucky | 40202 | — |
| Local Institution - 0020 | Baltimore | Maryland | 21287 | — |
| Local Institution - 0011 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0028 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0035 | Detroit | Michigan | 48202 | — |
| Local Institution - 0002 | St Louis | Missouri | 63110 | — |
| Local Institution - 0017 | Edison | New Jersey | 08820 | — |
| Local Institution - 0012 | Hackensack | New Jersey | 07601 | — |
| Local Institution - 0015 | New York | New York | 10032 | — |
| Local Institution - 0024 | New York | New York | 10065 | — |
| Local Institution - 0032 | Charlotte | North Carolina | 28204 | — |
| Preston Robert Tisch Brain Tumor Center at Duke University | Durham | North Carolina | 27710 | — |
| Local Institution - 0001 | Cleveland | Ohio | 44195 | — |
| Local Institution - 0027 | Columbus | Ohio | 43210 | — |
| Local Institution - 0098 | Allentown | Pennsylvania | 18103 | — |
| Local Institution - 0016 | Philadelphia | Pennsylvania | 19107 | — |
| Local Institution - 0021 | Charleston | South Carolina | 29425 | — |
| Erlanger Oncology & Hematology - Univ. of TN | Chattanooga | Tennessee | 37403 | — |
| Local Institution - 0008 | Nashville | Tennessee | 37232 | — |
| Local Institution - 0025 | Dallas | Texas | 75390-8575 | — |
| Local Institution - 0009 | Salt Lake City | Utah | 84112 | — |
| Local Institution - 0005 | Seattle | Washington | 98122 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 88 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02667587, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 17, 2025 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02667587 live on ClinicalTrials.gov.